ArticleScientific reports2025
Artificial intelligence-assisted quality control circles led by clinical pharmacists to improve the rational use of parenteral proton pump inhibitors among hospitalised patients.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Descriptive analysis of prescription interception patterns: characterizing medication safety risks in an outpatient setting.Frontiers in pharmacology · 2026Article
- The clinical value of PDCA cycle led by clinical pharmacists in optimizing the use of antimicrobial drugs in pediatric departments of primary hospitals.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Proton pump inhibitors (PPIs) are a class of drugs that inhibit gastric acid secretion and are commonly overused in clinical practice. We developed a quality control circle (QCC) assisted by artificial intelligence (AI) and led by clinical pharmacists to improve rational PPI use among patients in our hospital. A QCC team was established to follow QCC procedures. The root causes of inappropriate use were identified via AI-assisted brainstorming, and corresponding strategies were developed. The percentages of rational injectable PPI use before and after QCC implementation were calculated and compared. Radar charts were used to evaluate the capabilities of QCC members. Following QCC implementation, the percentage of rational injectable PPI use among hospitalised patients in our hospital increased from 66.51 to 93.43%, with a goal achievement percentage of 126.92% and a progression percentage of 40.47%. The increase in the percentage of rational PPI use was statistically significant (P < 0.001). Team cohesion, responsibility and proficiency in QCC techniques improved following QCC implementation. The standardised process for using injectable PPIs became more regulated following this process. AI-assisted, clinical pharmacist-led QCCs represent an efficient management tool for improving rational injectable PPI use among hospitalised patients, thereby promoting rational drug use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.